3M Enhances the Emphaze AEX Hybrid Purifier

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Emphaze AEX Hybrid Purifier
Emphaze™ AEX Hybrid Purifier (Medical Device News Magazine)

September 7, 2018

3M reports achieving high product purity early in the manufacturing process and improving efficiency and economics is important to biopharmaceutical manufacturers.

3M notes increasing removal of impurities like DNA and HCP during clarification improves the performance of downstream capture and polishing steps.

The 3M Emphaze™ AEX Hybrid Purifier meet these challenges through reduction of cell debris, DNA and HCP at clarification to help improve downstream process steps. The new Emphaze capsules are sterilization/sanitization compatible and can be used across various aqueous based biopharmaceutical processes, including vaccine purification. Additionally, the improved Emphaze AEX Hybrid Purifier products now feature two new laboratory capsules and one scale-up capsule that allows evaluations at laboratory and scale-up volumes.

“Customer input is critical in evaluating the performance and effectiveness of any product to maximize performance,” said Himanshu Nivsarkar, Global Marketing Manager, 3M Separation and Purification Sciences Division. “With the Emphaze AEX Hybrid Purifier, customers experience benefits in typical monoclonal antibody purification processes, including nominal 30% HCP and greater than 4 log DNA reduction. It has a consistent output turbidity (<5 NTU) leading to potential downsizing of the sterilizing grade membrane and increased product purity post-protein A. This also reduces turbidity post viral inactivation/neutralization step leading to a lower impurities load on the downstream AEX column, thus allowing customers to optimize their processes.”

Emphaze AEX Hybrid Purifier products are synthetic multi-mechanism single-use purifier products used for biopharmaceutical clarification. They deliver consistent, high purity clarified process fluid by removing soluble and insoluble impurities, such as DNA, HCP, and cell debris, through a combination of chromatographic and size exclusion mechanisms. Emphaze AEX Hybrid Purifier products combine three unique 3M technologies — advanced polymer materials, fine fiber nonwovens, and membranes — to deliver a synthetic clarifying product line containing a novel anion exchange nonwoven media and a fine particle, reduction membrane.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.